These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 32235008)

  • 21. Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer.
    Golan T; Barenboim A; Lahat G; Nachmany I; Goykhman Y; Shacham-Shmueli E; Halpern N; Brazowski E; Geva R; Wolf I; Goldes Y; Ben-Haim M; Klausner JM; Lubezky N
    Ann Surg Oncol; 2020 Oct; 27(10):3963-3970. PubMed ID: 32314163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis.
    Janssen QP; van Dam JL; Kivits IG; Besselink MG; van Eijck CHJ; Homs MYV; Nuyttens JJME; Qi H; van Santvoort HJ; Wei AC; de Wilde RF; Wilmink JW; van Tienhoven G; Groot Koerkamp B
    Ann Surg Oncol; 2021 Dec; 28(13):8297-8308. PubMed ID: 34142290
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population.
    Li X; Guo C; Li Q; Wei S; Zhang Q; Chen Y; Shen Y; Ma T; Li G; Gao S; Que R; Lou J; Yu R; Yuan Y; Wei Q; Huang P; Liang T; Bai X
    Oncologist; 2019 Mar; 24(3):301-e93. PubMed ID: 30459238
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intraoperative Radiation Mitigates the Effect of Microscopically Positive Tumor Margins on Survival Among Pancreatic Adenocarcinoma Patients Treated with Neoadjuvant FOLFIRINOX and Chemoradiation.
    Sekigami Y; Michelakos T; Fernandez-Del Castillo C; Kontos F; Qadan M; Wo JY; Harrison J; Deshpande V; Catalano O; Lillemoe KD; Hong TS; Ferrone CR
    Ann Surg Oncol; 2021 Aug; 28(8):4592-4601. PubMed ID: 33393047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer.
    Boone BA; Steve J; Krasinskas AM; Zureikat AH; Lembersky BC; Gibson MK; Stoller RG; Zeh HJ; Bahary N
    J Surg Oncol; 2013 Sep; 108(4):236-41. PubMed ID: 23955427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FOLFIRINOX-based neoadjuvant chemoradiotherapy for borderline and locally advanced pancreatic cancer: A pilot study from a tertiary centre.
    Pouypoudat C; Buscail E; Cossin S; Cassinotto C; Terrebonne E; Blanc JF; Smith D; Marty M; Dupin C; Laurent C; Dabernat S; Chiche L; Vendrely V
    Dig Liver Dis; 2019 Jul; 51(7):1043-1049. PubMed ID: 31000479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX.
    Choi YJ; Byun Y; Kang JS; Kim HS; Han Y; Kim H; Kwon W; Oh DY; Paik WH; Lee SH; Ryu JK; Kim YT; Lee K; Kim H; Chie EK; Jang JY
    Gut Liver; 2021 May; 15(3):466-475. PubMed ID: 32839360
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
    Hashemi-Sadraei N; Gbolahan OB; Salfity H; O'Neil B; House MG; Shahda S
    Am J Clin Oncol; 2018 Oct; 41(10):982-985. PubMed ID: 28968257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer.
    Miller PN; Romero-Hernandez F; Calthorpe L; Wang JJ; Kim SS; Corvera CU; Hirose K; Kirkwood KS; Hirose R; Maker AV; Alseidi AA; Adam MA; Kim GE; Tempero MA; Ko AH; Nakakura EK
    Ann Surg Oncol; 2024 Sep; 31(9):6147-6156. PubMed ID: 38879670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Borderline or locally advanced pancreatic adenocarcinoma: A single center experience on the FOLFIRINOX induction regimen.
    Garnier J; Ewald J; Marchese U; Gilabert M; Moureau-Zabotto L; Giovannini M; Poizat F; Delpero JR; Turrini O
    Eur J Surg Oncol; 2020 Aug; 46(8):1510-1515. PubMed ID: 32146053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of conversion surgery in patients with pancreatic cancer who underwent neoadjuvant or palliative FOLFIRINOX treatment using baseline and follow-up CT.
    Park SJ; Kim JH; Joo I; Han JK
    Abdom Radiol (NY); 2021 Oct; 46(10):4765-4778. PubMed ID: 34085090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis.
    Barenboim A; Lahat G; Geva R; Nachmany I; Nakache R; Goykhman Y; Brazowski E; Rosen G; Isakov O; Wolf I; Klausner JM; Lubezky N
    Eur J Surg Oncol; 2018 Oct; 44(10):1619-1623. PubMed ID: 30146251
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
    Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
    Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer.
    Lee W; Oh M; Kim JS; Sung M; Hong K; Kwak BJ; Park Y; Jun E; Song KB; Hwang DW; Lee JH; Yoo C; Kim KP; Park I; Jeong JH; Chang HM; Ryoo BY; Lee JB; Kim SC
    Int J Surg; 2024 Jul; 110(7):4074-4082. PubMed ID: 38537071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Important CT and histopathological findings for recurrence and overall survival in patients with pancreatic ductal adenocarcinoma who underwent surgery after neoadjuvant FOLFIRINOX.
    Park SJ; Kim JH; Joo I; Lee KB; Han JK
    Eur Radiol; 2021 Jun; 31(6):3616-3626. PubMed ID: 33201279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies.
    Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Ghilardi M; Lonati V; Aitini E; Barni S;
    Pancreas; 2015 May; 44(4):515-21. PubMed ID: 25872127
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Initial experience with neoadjuvant FOLFIRINOX as first line therapy for locally advanced pancreatic cancer.
    Karachaliou GS; Lazarou V; Giannis D; Astras G; Moris D; Petrou A
    J BUON; 2020; 25(5):2525-2527. PubMed ID: 33277879
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.
    Nywening TM; Wang-Gillam A; Sanford DE; Belt BA; Panni RZ; Cusworth BM; Toriola AT; Nieman RK; Worley LA; Yano M; Fowler KJ; Lockhart AC; Suresh R; Tan BR; Lim KH; Fields RC; Strasberg SM; Hawkins WG; DeNardo DG; Goedegebuure SP; Linehan DC
    Lancet Oncol; 2016 May; 17(5):651-62. PubMed ID: 27055731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience.
    Faris JE; Blaszkowsky LS; McDermott S; Guimaraes AR; Szymonifka J; Huynh MA; Ferrone CR; Wargo JA; Allen JN; Dias LE; Kwak EL; Lillemoe KD; Thayer SP; Murphy JE; Zhu AX; Sahani DV; Wo JY; Clark JW; Fernandez-del Castillo C; Ryan DP; Hong TS
    Oncologist; 2013; 18(5):543-8. PubMed ID: 23657686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic activity by FDG-PET/CT after neoadjuvant chemotherapy in borderline resectable and locally advanced pancreatic cancer and association with survival.
    Lee W; Oh M; Kim JS; Park Y; Kwon JW; Jun E; Song KB; Lee JH; Hwang DW; Yoo C; Kim KP; Jeong JH; Chang HM; Ryoo BY; Park SY; Kim SC
    Br J Surg; 2021 Dec; 109(1):61-70. PubMed ID: 34378010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.